Regencell Bioscience Holdings Limited
RGC
Rank in Stocks
#3521
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in... Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
Share Price
$10.58
Market Cap
$5.25B
Change (1 day)
5.27%
Change (1 year)
-37.62%
Country
HK
Trade Regencell Bioscience Holdings Limited (RGC)
Category
Healthcare
Earnings for Regencell Bioscience Holdings Limited (RGC)
Earnings in Jun 2026 TTM: $-11.70M
According to Regencell Bioscience Holdings Limited latest financial reports the company's current earnings are $-11.70M. In 2024 the company made an earning of $-4.36M, an increase over its 2023 earnings that were of $-6.06M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Regencell Bioscience Holdings Limited from 2019 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-11.70M | 226.49% |
| 2025 | $-3.58M | -17.85% |
| 2024 | $-4.36M | -28.03% |
| 2023 | $-6.06M | -20.18% |
| 2022 | $-7.59M | 463.92% |
| 2021 | $-1.35M | 65.78% |
| 2020 | $-812.37K | 107.77% |
| 2019 | $-390.99K | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | -15,179.14% |
IN
|
